Patent-drug price board to review guidelines
- Brand-name drug companies fail to meet R&D commitments. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;8/15/2006, Vol. 175 Issue 4, p344
This article focuses on a report released by the Patented Medicines Prices Review Board which indicated that spending on brand name drugs continues to increase while outlays for research and development remained lower in Canada. Drug sales increased by 1.3 percent to $16.1 billion. Bill C-22,...
- Drug patent issues back on agenda. Highleyman, Liz // Bay Area Reporter;10/25/2001, Vol. 31 Issue 43, p17
Reports on the issue of drug pricing and patents in the U.S. Importance of purchasing drugs from multiple generic drug manufacturers; Federal law allowing the government to purchase products for official use from alternative sources; Licensing provision of the World Trade Organization Trade...
- Patent Medicine. Baker, Dean // American Prospect;1/29/2001, Vol. 12 Issue 2, p13
Focuses on the pricing monopoly created by the U.S. patent system for prescription drugs. Recommended solution to eliminating costs with regard to patent terms and drug research; Benefits of challenging the system; Negative impact of the system on improving drug research.
- Thailand's pharmaceutical stand heightens international row. Sanders, Sol W. // East-Asia-Intel Reports;2/14/2007, p13
The article reports that the decision of Thailand to allow either the manufacture or import of generic versions of Abbott's human immunodeficiency virus (HIV) treatment Kaletra and Sanofi-Aventis' blood clot drug Plavix, heightens international debate over drug pricing. The U.S. has been...
- Atorvastatin price crashes by 93%. // Pulse;5/9/2012, p2
The article reports on the drop of the price of atorvastatin by 93% before the expiration of its patent, which lead to the restriction on its use.
- US prescription sales continue to climb. // PharmacoEconomics & Outcomes News;May2015, Vol. 727 Issue 1, p32
The article discusses research being done on the trends in prescription drug expenditures and projections in the U.S. for 2015, which references a study by G. T. Schumock et al. published in the May 2015 issue of the "American Journal of Health-System Pharmacy."
- Could Canada's compulsory Rx licensing work in U.S.? Conlan, Michael F. // Drug Topics;8/16/93, Vol. 137 Issue 16, p56
Discusses the effects of changes in Canada's patent laws on its prescription drug prices. Introduction of legislation in Congress to create a United States version of Canada's Patented Medicines Price Review Board (PMPRB); Canada as having highest new drug prices; Compulsory licensing; Length...
- Medicines without barriers. Hubbard, Tim; Love, Jamie // New Scientist;6/14/2003, Vol. 178 Issue 2399, p29
This article argues that an international patent system is not essential for the development of new drugs. This system leads to high prices of drugs and unequal access to them. Today's high drug prices are a consequence of intellectual property enforcement mechanisms that are designed to pay for...
- Drug-patent loopholes cited for higher costs. // New Hampshire Business Review;02/22/2002, Vol. 24 Issue 4, p31
Focuses on how loopholes in New Hampshire's drug-patent policy increase drug costs. Trends among drug companies in regard to drug patents; Effect on genetic drugs; Action taken by the local government in response to the matter.